Skip to main content
S

SCL Science Inc. — Investor Relations & Filings

Ticker · 246960 ISIN · KR7246960009 KO Professional, scientific and technical activities
Open in API
Filings indexed 309 across all filing types
Latest filing 2023-03-15 AGM Information
Country KR South Korea
Listing KO 246960

About SCL Science Inc.

https://sclscience.com/en

SCL Science Inc., formerly InnoTherapy Inc., is a healthcare company focused on digital innovation and advanced medical technologies. The company develops and commercializes medical hemostatic agents based on its proprietary biomimetic technology, including the Bio-inspired Medical Materials (BiMM) product line. Leveraging 40 years of expertise in medical science, SCL Science is also dedicated to building a digital healthcare ecosystem using artificial intelligence and high-quality medical data. Its services extend to clinical trial analysis, bio-logistics, and an expanding drug discovery platform focused on AI-driven cancer vaccine development. The company serves hospitals, research laboratories, and other medical institutions.

Recent filings

Filing Released Lang Actions
주주총회소집공고
AGM Information Classification · 1% confidence The document is a 'Notice of Annual General Meeting' (주주총회소집공고) for InnoTherapy. It contains the meeting agenda, details on voting procedures (electronic voting), and management information including board activity reports and financial statements (balance sheets, income statements) for the fiscal year 2022. This document is a standard proxy statement/notice package sent to shareholders to inform them of the upcoming AGM and solicit their votes, which falls under the Proxy Solicitation & Information Statement category.
2023-03-15 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 1% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy), which is a standard regulatory filing in South Korea (Form 3.6) used to solicit shareholder votes for an upcoming Annual General Meeting (AGM). It contains details about the meeting, voting procedures, and proxy solicitation, which aligns with the Proxy Solicitation & Information Statement category.
2023-03-15 Korean
주요사항보고서(유상증자결정)
Capital/Financing Update Classification · 1% confidence The document is a 'Major Matter Report' (주요사항보고서) from InnoTherapy, specifically detailing a 'Decision on Paid-in Capital Increase' (유상증자결정). It outlines the issuance of new shares, the purpose of the capital raise (facility, operation, etc.), the method (third-party allocation), and details regarding the allottees. This falls under the category of capital structure changes and financing activities.
2023-03-13 Korean
대표이사변경
Board/Management Information Classification · 1% confidence The document is a formal announcement regarding a change in the company's representative director (CEO). It details the previous and new representative directors, the reason for the change (management efficiency), and the effective date. This falls directly under the category of Board/Management Information (MANG).
2023-03-13 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Financial Supervisory Service in South Korea. This type of filing is a mandatory disclosure when a director or major shareholder acquires or changes their stake in the company. According to the provided definitions, this falls under 'Director's Dealing' (DIRS), which covers personal share transactions and ownership reports by company directors and executives.
2023-02-07 Korean
자산재평가결과(자율공시)
Regulatory Filings Classification · 1% confidence The document is a formal disclosure regarding the results of an asset revaluation (land and buildings) for the company InnoTherapy. It details the revaluation date, the difference between book value and revalued amount, and the accounting impact on equity. Since this is a specific regulatory disclosure regarding financial assets that does not fit into the other specialized categories like 10-K, IR, or ER, it falls under the general regulatory filing category.
2023-01-06 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.